Gyre Therapeutics, Inc. (GYRE) — SEC Filings
Gyre Therapeutics, Inc. (GYRE) — 36 SEC filings. Latest: DEFA14A (May 4, 2026). Includes 21 8-K, 6 10-Q, 2 DEF 14A.
View Gyre Therapeutics, Inc. on SEC EDGAR
Overview
Gyre Therapeutics, Inc. (GYRE) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 7, 2025: GYRE THERAPEUTICS, INC. reported a net income of $5.9 million for the three months ended September 30, 2025, a significant increase from $2.9 million in the same period of 2024. Revenues also grew to $30.6 million for the quarter, up from $25.5 million year-over-year. For the nine months ended Septe
Sentiment Summary
Across 36 filings, the sentiment breakdown is: 3 bearish, 32 neutral, 1 mixed. The dominant filing sentiment for Gyre Therapeutics, Inc. is neutral.
Filing Type Overview
Gyre Therapeutics, Inc. (GYRE) has filed 1 DEFA14A, 21 8-K, 6 10-Q, 2 DEF 14A, 1 SC 13D, 1 10-K, 1 SC 13G/A, 1 SC 13D/A, 2 8-K/A with the SEC between Jan 2024 to May 2026.
Filings by Year
Recent SEC Filings (36)
Risk Profile
Risk Assessment: Of GYRE's 30 recent filings, 2 were flagged as high-risk, 15 as medium-risk, and 13 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $79.4M |
| Net Income | $11.2M |
| EPS | Not Disclosed |
| Debt-to-Equity | Not Disclosed |
| Cash Position | $40.4M |
| Operating Margin | Not Disclosed |
| Total Assets | Not Disclosed |
| Total Debt | Not Disclosed |
Key Executives
- Executive Chairman of Gyre's Board of Directors
- Gyre's Chief Operating Officer
- Weiguo Ye
- Luo Ying
- Dr. Jonathan G. Drachman
- Ms. Sarah E. Kelly
- Dr. Jonathan M. Roth
- Dr. David M. Chang
Industry Context
GYRE THERAPEUTICS operates within the biopharmaceutical sector, with a strategic focus on anti-fibrotic drugs through its significant stake in Gyre Pharmaceuticals in China. This market is characterized by high R&D costs, long development cycles, and stringent regulatory oversight. Success hinges on innovation, clinical trial outcomes, and market access in a competitive landscape.
Top Tags
corporate-governance (6) · financials (6) · 10-Q (4) · pharmaceuticals (4) · management-change (3) · corporate-actions (3) · financial-reporting (3) · Gyre Therapeutics (3) · Biotechnology (2) · Pharmaceuticals (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Cash and cash equivalents | $40.4M | Increased from $11.8M at December 31, 2024, indicating improved liquidity. |
| Revenues for Q3 2025 | $30.6M | Increased from $25.5M in Q3 2024, showing quarterly growth. |
| Net income for Q3 2025 | $5.9M | Increased from $2.9M in Q3 2024, a significant quarterly improvement. |
| Revenues for nine months ended Sep 30, 2025 | $79.4M | Slightly increased from $77.9M in the prior year period. |
| Net income for nine months ended Sep 30, 2025 | $11.2M | Decreased from $17.3M in the prior year period, indicating a year-to-date decline. |
| Accumulated deficit | $66.7M | Improved from $73.5M at December 31, 2024, reducing historical losses. |
| Net cash provided by financing activities | $24.1M | Primarily from a $23.0M public offering, significantly boosting cash reserves. |
| Common shares outstanding | 90,890,381 | As of September 30, 2025, reflecting share issuance activities. |
| Indirect interest in Gyre Pharmaceuticals | 69.7% | Represents the company's controlling stake in its key operating subsidiary. |
| Net cash provided by operating activities | $6.6M | For the nine months ended September 30, 2025, a positive shift from the prior year. |
| Revenue | $0 | for three and six months ended June 30, 2025, indicating pre-commercial stage |
| Net Loss | $15.2M | for three months ended June 30, 2025, up from $10.5M in Q2 2024 |
| Cash and Cash Equivalents | $10.0M | as of June 30, 2025, down from $20.0M at December 31, 2024 |
| Underwritten Public Offering Date | 2025-05-22 | key capital raise event |
| Reporting Period End | 2025-03-31 | The 10-Q covers financial information up to this date. |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Gyre Therapeutics, Inc. (GYRE)?
Gyre Therapeutics, Inc. has 36 recent SEC filings from Jan 2024 to May 2026, including 21 8-K, 6 10-Q, 2 DEF 14A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of GYRE filings?
Across 36 filings, the sentiment breakdown is: 3 bearish, 32 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Gyre Therapeutics, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Gyre Therapeutics, Inc. (GYRE) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Gyre Therapeutics, Inc.?
Key financial highlights from Gyre Therapeutics, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for GYRE?
The investment thesis for GYRE includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Gyre Therapeutics, Inc.?
Key executives identified across Gyre Therapeutics, Inc.'s filings include Executive Chairman of Gyre's Board of Directors, Gyre's Chief Operating Officer, Weiguo Ye, Luo Ying, Dr. Jonathan G. Drachman and 3 others.
What are the main risk factors for Gyre Therapeutics, Inc. stock?
Of GYRE's 30 assessed filings, 2 were flagged high-risk, 15 medium-risk, and 13 low-risk.
What are recent predictions and forward guidance from Gyre Therapeutics, Inc.?
Forward guidance and predictions for Gyre Therapeutics, Inc. are extracted from SEC filings as they are enriched.